Trial Profile

A Phase 3, Randomised, Double-blind Study to Compare the Efficacy, Safety, PK and Immunogenicity Between SB8 (Proposed Bevacizumab Biosimilar) and Avastin in Subjects With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Samsung Bioepis

21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
26 Sep 2019 Results published in a Samsung Bioepis media release.
26 Sep 2019 According to a Samsung Bioepis media release, results will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com